Defining molecular risk in ALK(+) NSCLC

Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancers (NSCLC) have the best prognosis among metastatic pulmonary malignancies, with a median patient survival currently exceeding 5 years. While this is definitely a major therapeutic success for thoracic oncology, it may not be entirel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Christopoulos, Petros, Budczies, Jan, Kirchner, Martina, Dietz, Steffen, Sültmann, Holger, Thomas, Michael, Stenzinger, Albrecht
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2019
Assuntos:
Research Perspective
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517105/
https://ncbi.nlm.nih.gov/pubmed/31139322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26886
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados